semaglutide 1.25 mg Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) and reduced Ozempic® (semaglutide) Injection 0.25mg, 0.5

doi:10.1016/j.ab.2003.07.023

Adding or increasing resistance training, adjusting protein intake, or discussing a dose adjustment with your Rivas provider are more productive levers

Injectable GLP-1 drugs like Ozempic were originally created to treat diabetes, but theyre now becoming famous for being a celebrity weight loss drug causing a shortage for patients who actually need it to treat their medical conditions

If you have persistent nausea, vomiting, or diarrhea while taking Ozempic, let your provider know right away

Any other new, concerning, or persistent symptom that develops after starting the supplement